Published in Onco Targets Ther on March 07, 2016
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med (2009) 65.36
Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst (1995) 18.86
The global health burden of infection-associated cancers in the year 2002. Int J Cancer (2006) 13.57
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol (2012) 9.28
Interleukin-10 determines viral clearance or persistence in vivo. Nat Med (2006) 8.01
An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet (1997) 5.65
Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis (2011) 2.88
Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer (1997) 2.30
The search for infectious causes of human cancers: where and why. Virology (2009) 2.04
Association of interleukin-6 circulating levels with coronary artery disease: a meta-analysis implementing mendelian randomization approach. Int J Cardiol (2012) 1.57
Interleukin-10 and interferon-gamma gene polymorphisms in patients with nasopharyngeal carcinoma. Int J Immunogenet (2008) 1.49
Viruses associated with human cancer. Biochim Biophys Acta (2007) 1.47
Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation (2003) 1.37
Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer (2001) 1.23
Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol (2000) 1.22
Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun (2006) 1.20
Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol (2007) 1.18
Current status of interleukin-10 and regulatory T-cells in cancer. Curr Opin Oncol (2013) 1.17
Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int J Cancer (2007) 1.15
Detection of Epstein-Barr virus and human papillomavirus in head and neck tumors. J Clin Microbiol (1993) 1.07
Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest (1998) 1.07
Human papilloma virus, herpes simplex virus and epstein barr virus in oral squamous cell carcinoma from eight different countries. Anticancer Res (2012) 1.03
Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother (2005) 0.99
Correlation between IL-10 gene expression and HPV infection in cervical cancer: a mechanism for immune response escape. Cancer Invest (2008) 0.98
Quantitative analysis of IL-10 and IFN-gamma mRNA levels in normal cervix and human papillomavirus type 16 associated cervical precancer. J Pathol (2001) 0.96
Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer (2005) 0.96
Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett (2002) 0.94
Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk Lymphoma (2003) 0.93
Host genetic control of HPV 16 titer in carcinoma in situ of the cervix uteri. Int J Cancer (2002) 0.92
Association between human papillomavirus and Epstein-Barr virus infections in human oral carcinogenesis. Med Hypotheses (2009) 0.92
Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clin Pharmacol Ther (1997) 0.91
Genetic variants in immunoregulatory genes and risk for childhood lymphomas. Eur J Haematol (2009) 0.89
Association between cytokine gene polymorphisms and cervical cancer in a Chinese population. Eur J Obstet Gynecol Reprod Biol (2011) 0.88
Association of TNFA (-308G>A) and IL-10 (-819C>T) promoter polymorphisms with risk of cervical cancer. Int J Gynecol Cancer (2009) 0.88
IL-10 expression is regulated by HPV E2 protein in cervical cancer cells. Mol Med Rep (2011) 0.88
IL-10 expression is associated with the expression of platelet-derived endothelial cell growth factor and prognosis in oral and oropharyngeal carcinoma. Cancer Lett (1999) 0.88
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. Leuk Res (2009) 0.88
Consumption of fruit, vegetables, and other food groups and the risk of nasopharyngeal carcinoma. Cancer Causes Control (2013) 0.87
TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol (2012) 0.87
Human papillomavirus and Epstein-Barr virus co-infection in cervical carcinoma in Algerian women. Virol J (2013) 0.86
Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol (2000) 0.85
Ethnic differences in allelic distribution of IFN-g in South African women but no link with cervical cancer. J Carcinog (2003) 0.85
Relationship of Epstein-Barr virus and interleukin 10 promoter polymorphisms with the risk and clinical outcome of childhood Burkitt lymphoma. PLoS One (2012) 0.84
Interleukin-10 promoter variants predict HPV-positive tumors and survival of squamous cell carcinoma of the oropharynx. FASEB J (2013) 0.83
Elevated pretreatment serum levels of Il-10 are associated with a poor prognosis in Hodgkin's disease, the milan cancer institute experience. Med Oncol (2000) 0.83
Interleukin-10 gene promoter polymorphisms and the risk of nasopharyngeal carcinoma. Tissue Antigens (2007) 0.83
Effect of anti-inflammatory (IL-4, IL-10) cytokine genes in relation to risk of cervical carcinoma. Am J Clin Oncol (2012) 0.83
The criteria to confirm the role of Epstein-Barr virus in nasopharyngeal carcinoma initiation. Int J Mol Sci (2012) 0.82
Association of interleukin-10 (IL10) promoter genotypes with nasopharyngeal carcinoma risk in Taiwan. Anticancer Res (2013) 0.81
Interleukin-10 -1082 gene polymorphism and susceptibility to cervical cancer among Japanese women. Jpn J Clin Oncol (2010) 0.81
Significant association of Interleukin-10 genotypes and oral cancer susceptibility in Taiwan. Anticancer Res (2014) 0.81
Genetic predisposition to increased blood cholesterol and triglyceride lipid levels and risk of Alzheimer disease: a Mendelian randomization analysis. PLoS Med (2014) 0.81
Nasopharyngeal and hypopharyngeal carcinoma risk among immigrants in Sweden. Int J Cancer (2010) 0.80
Epstein-Barr virus infection and single nucleotide polymorphisms in the promoter region of interleukin 10 gene in patients with Hodgkin lymphoma. Arch Pathol Lab Med (2007) 0.80
Polymorphisms in the interleukin-10 and interferon gamma genes in Hodgkin lymphoma. Leuk Lymphoma (2003) 0.80
Effects of IL-10 haplotype and atomic bomb radiation exposure on gastric cancer risk. Radiat Res (2013) 0.79
A pilot case-control association study of cytokine polymorphisms in Brazilian women presenting with HPV-related cervical lesions. Eur J Obstet Gynecol Reprod Biol (2008) 0.79
Cervical cancer with human papilloma virus and Epstein Barr virus positive. J Carcinog (2006) 0.78
An interleukin-10 gene polymorphism associated with the development of cervical lesions in women infected with Human Papillomavirus and using oral contraceptives. Infect Genet Evol (2013) 0.77
Interleukin-6 and interleukin-10 gene promoter polymorphisms and risk of endemic Burkitt lymphoma. Am J Trop Med Hyg (2014) 0.76